Darby and her team have demonstrated that there is a linear relationship between the dose of radiation delivered incidentally to the heart during breast cancerradiotherapy and the subsequent risk of ischaemicheart disease, and that the absolute size of the radiation-related risk is bigger for women already at increased risk of heart disease.[6][8]
She and her team have also estimated the absolute size of the benefit of radiotherapy to breast cancer patients and their work is enabling comparison of the likely absolute benefit of radiotherapy with its likely absolute risk for individual patients.[6] Therefore, it is now becoming possible to assess which patients can receive standard radiotherapy, which should be considered for advanced techniques, and which should avoid radiotherapy altogether.[6][9]
^Darby, S. C.; Whitely, E.; Howe, G. R.; Hutchings, S. J.; Kusiak, R. A.; Lubin, J. H.; Morrison, H. I.; Tirmarche, M.; Tomasek, L.; Radford, E. P.; Roscoe, R. J.; Samet, J. M.; Yao, S. X. (1995). "Radon and Cancers Other Than Lung Cancer in Underground Miners: a Collaborative Analysis of 11 Studies". JNCI Journal of the National Cancer Institute. 87 (5): 378–384. doi:10.1093/jnci/87.5.378. ISSN0027-8874. PMID7853419.
^Darby, Sarah C; Ewart, David W; Giangrande, Paul LF; Spooner, Rosemary JD; Rizza, Charles R; Dusheiko, Geoffrey M; Lee, Christine A; Ludlam, Christopher A; Preston, F Eric (1997). "Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C". The Lancet. 350 (9089): 1425–1431. doi:10.1016/S0140-6736(97)05413-5. ISSN0140-6736. PMID9371165. S2CID20692603.
^ abcdefgAnon (2019). "Sarah Darby". royalsociety.org. London: Royal Society. Archived from the original on 2019-04-24. One or more of the preceding sentences incorporates text from the royalsociety.org website where:
^Darby, Sarah C; McGale, Paul; Taylor, Carolyn W; Peto, Richard (2005). "Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300 000 women in US SEER cancer registries". The Lancet Oncology. 6 (8): 557–565. doi:10.1016/S1470-2045(05)70251-5. ISSN1470-2045. PMID16054566.